BR112017017418A2 - heterociclos bicíclicos como inibidores de fgfr - Google Patents

heterociclos bicíclicos como inibidores de fgfr

Info

Publication number
BR112017017418A2
BR112017017418A2 BR112017017418-9A BR112017017418A BR112017017418A2 BR 112017017418 A2 BR112017017418 A2 BR 112017017418A2 BR 112017017418 A BR112017017418 A BR 112017017418A BR 112017017418 A2 BR112017017418 A2 BR 112017017418A2
Authority
BR
Brazil
Prior art keywords
bicyclic heterocycles
fgfr inhibitors
fgfr
inhibitors
heterocycles
Prior art date
Application number
BR112017017418-9A
Other languages
English (en)
Other versions
BR112017017418A8 (pt
BR112017017418B1 (pt
Inventor
Lu Liang
Shen Bo
Sokolsky Alexander
Wang Xiaozhao
Wu Liangxing
Yao Wenqing
Ye Yingda
Original Assignee
Incyte Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55442925&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017017418(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Incyte Corporation filed Critical Incyte Corporation
Publication of BR112017017418A2 publication Critical patent/BR112017017418A2/pt
Publication of BR112017017418A8 publication Critical patent/BR112017017418A8/pt
Publication of BR112017017418B1 publication Critical patent/BR112017017418B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Abstract

a presente descrição refere-se a heterociclos bicíclicos e a composições farmacêuticas dos mesmos, que são inibidores da enzima fgfr3 e/ou fgfr4 e que são úteis no tratamento de doenças as-sociadas ao fgfr.
BR112017017418-9A 2015-02-20 2016-02-19 Heterociclos bicíclicos como inibidores de fgfr, seu uso e composição farmacêutica que os compreende BR112017017418B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562118698P 2015-02-20 2015-02-20
US62/118,698 2015-02-20
US201562170936P 2015-06-04 2015-06-04
US62/170,936 2015-06-04
PCT/US2016/018787 WO2016134320A1 (en) 2015-02-20 2016-02-19 Bicyclic heterocycles as fgfr inhibitors

Publications (3)

Publication Number Publication Date
BR112017017418A2 true BR112017017418A2 (pt) 2018-04-10
BR112017017418A8 BR112017017418A8 (pt) 2023-01-24
BR112017017418B1 BR112017017418B1 (pt) 2023-05-23

Family

ID=

Also Published As

Publication number Publication date
SG10201913036RA (en) 2020-02-27
SG11201706287PA (en) 2017-09-28
CA2976790A1 (en) 2016-08-25
PH12017501481A1 (en) 2018-02-05
AU2016219822B2 (en) 2020-07-09
ECSP17062712A (es) 2017-11-30
UA121669C2 (uk) 2020-07-10
US9708318B2 (en) 2017-07-18
BR112017017418A8 (pt) 2023-01-24
AU2020250211B2 (en) 2022-09-29
EA201791866A1 (ru) 2017-12-29
MY197720A (en) 2023-07-10
PH12017501481B1 (en) 2018-02-05
US10632126B2 (en) 2020-04-28
US20190269693A1 (en) 2019-09-05
CL2017002123A1 (es) 2018-03-16
CR20170390A (es) 2017-10-23
ES2895769T3 (es) 2022-02-22
KR102632018B1 (ko) 2024-02-02
CA2976790C (en) 2024-02-27
EP3617205A1 (en) 2020-03-04
CN113004278A (zh) 2021-06-22
US20170290839A1 (en) 2017-10-12
EA038045B1 (ru) 2021-06-28
CN113004278B (zh) 2023-07-21
TW201639838A (zh) 2016-11-16
JP6689871B2 (ja) 2020-04-28
MX2017010673A (es) 2018-03-21
HK1246794A1 (zh) 2018-09-14
AU2020250211A1 (en) 2020-11-05
KR20170127467A (ko) 2017-11-21
AU2016219822A1 (en) 2017-08-31
TWI712601B (zh) 2020-12-11
US20160244449A1 (en) 2016-08-25
MA51229A (fr) 2021-03-24
JP2018511573A (ja) 2018-04-26
IL253691A0 (en) 2017-09-28
US10251892B2 (en) 2019-04-09
ES2751669T9 (es) 2020-05-21
WO2016134320A1 (en) 2016-08-25
US11173162B2 (en) 2021-11-16
US20200306256A1 (en) 2020-10-01
EP3259269B9 (en) 2020-03-04
MX2020004108A (es) 2022-01-03
CN107438607B (zh) 2021-02-05
IL253691B (en) 2020-11-30
CO2017008795A2 (es) 2018-01-16
PE20171514A1 (es) 2017-10-20
CN107438607A (zh) 2017-12-05
EP3259269A1 (en) 2017-12-27
JP2020121994A (ja) 2020-08-13
ES2751669T3 (es) 2020-04-01
EP3259269B1 (en) 2019-09-04
EP3617205B1 (en) 2021-08-04

Similar Documents

Publication Publication Date Title
PH12017501481A1 (en) Bicyclic heterocycles as fgfr inhibitors
BR112017017727A8 (pt) Heterociclos bicíclicos como inibidores de fgfr4
BR112015026307A2 (pt) heterociclo bicíclicos como inibidores de fgfr
PH12019502809A1 (en) Substituted tricyclic compounds as fgfr inhibitors
BR112022007163A2 (pt) Heterociclos bicíclicos como inibidores de fgfr
MX2018007703A (es) Inhibidores de la interaccion de menina-linaje leucemico mixto.
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
WO2015116868A3 (en) Molecular profiling of immune modulators
BR112018003780A2 (pt) composições que compreendem um composto de urolitina
BR112016028948A2 (pt) ?composição bifásica?
EA202190877A1 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr
BR112015017241A2 (pt) doadores de nitroxil com índice terapêutico melhorado
EA202091923A1 (ru) Замещенные трициклические соединения как ингибиторы fgfr

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: INCYTE HOLDINGS CORPORATION (US)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/02/2016, OBSERVADAS AS CONDICOES LEGAIS